Linked Life Data

16487172

Source:http://linkedlifedata.com/resource/pubmed/id/16487172

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-2-20
pubmed:abstractText
Patients treated with multicycle chemotherapy can exhibit large interindividual heterogeneity of haematotoxicity. We describe how a biomathematical model of human granulopoiesis can be used to design risk-adapted dose-dense chemotherapies, leading to more similar leucopoenias in the population. Calculations were performed on a large data set for cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP)-like chemotherapies for aggressive non-Hodgkin lymphoma. Age, gender, Eastern Cooperative Oncology Group performance status, lactate dehydrogenase and the degree of leucopoenia within the first therapy cycle were used to stratify patients into groups with different expected severity of leucopoenia. We estimated risk-specific bone marrow toxicities depending on the drug doses administered. These toxicities were used to derive risk-adapted therapy schedules. We determined different doses of cyclophosphamide and additional etoposide for patients treated with CHOP-14. Alternatively, the model predicted that further reductions of cycle duration were feasible in groups with low toxicity. We also used the model to identify appropriate granulocyte colony-stimulating factor (G-CSF) schedules. In conclusion, we present a method to estimate the potential of risk-specific dose adaptation of different cytotoxic drugs in order to design chemotherapy protocols that result in decreased diversity of leucopoenia between patients, to develop dose-escalation strategies in cases of low leucopoenic reaction and to determine optimal G-CSF support.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-1048
pubmed:author
pubmed:issnType
Print
pubmed:volume
132
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
723-35
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16487172-Antineoplastic Agents, pubmed-meshheading:16487172-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16487172-Bone Marrow, pubmed-meshheading:16487172-Cyclophosphamide, pubmed-meshheading:16487172-Dose-Response Relationship, Drug, pubmed-meshheading:16487172-Doxorubicin, pubmed-meshheading:16487172-Drug Administration Schedule, pubmed-meshheading:16487172-Etoposide, pubmed-meshheading:16487172-Female, pubmed-meshheading:16487172-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:16487172-Granulocytes, pubmed-meshheading:16487172-Humans, pubmed-meshheading:16487172-Leukocyte Count, pubmed-meshheading:16487172-Leukopenia, pubmed-meshheading:16487172-Lymphoma, Non-Hodgkin, pubmed-meshheading:16487172-Male, pubmed-meshheading:16487172-Mathematics, pubmed-meshheading:16487172-Middle Aged, pubmed-meshheading:16487172-Models, Biological, pubmed-meshheading:16487172-Prednisone, pubmed-meshheading:16487172-Risk Factors, pubmed-meshheading:16487172-Severity of Illness Index, pubmed-meshheading:16487172-Vincristine
pubmed:year
2006
pubmed:articleTitle
Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia.
pubmed:affiliation
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. markus.scholz@imise.uni-leipzig.de
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't